UNIVERSITY OF MIAMI MILLER SCHOOL of MEDICINE

# 540: Patient Specific Factors That Correlate With Sacral Neuromodulation Success In Underactive Bladder


Greeshma Venigalla<sup>1</sup>, Braian Rene Ledesma<sup>1</sup>, Alan Wein<sup>1</sup>, Katherine A. Amin<sup>1</sup>, <u>Raveen Syan<sup>1</sup></u> <sup>1</sup>Department of Urology, Division of Female Urology, University of Miami, Miami, FL

# Aims of study

- SNM is a minimally invasive and effective therapy which may be used for patients with underactive bladder (UAB) who do not respond to conservative management as well.
- However, not all patients respond to SNS, and identifying predictors of success is important for optimizing patient selection and outcomes.
- Urodynamic variables, such as Pdet, Qmax, and bladder capacity, have been suggested as predictors of SNS success in UAB patients.
- Comparing the predictive value of these urodynamic variables in predicting SNS success in UAB patients may provide important insights into the use of urodynamic variables in guiding clinical decision-making.

# Study design, materials and methods

 Retrospective review of 32 patients who underwent SNS for UAB management at the University of Miami between January 2016 - December 2020



Sacral neuromodulation may be an effective treatment option for patients with underactive bladder



- Preoperative urodynamic variables maximum detrusor pressure (Pdet max), detrusor pressure at maximum flow rate (Pdet at Qmax), average flow rate (Qave), maximum flow rate (Qmax), post-void residual (PVR), end filling detrusor pressure (End Filling Pdet), and catheter use.
- Proportion of patients who had successful final placement of SNS IPG device.

	Success	Non-success	p value
Age	57	57	0.99
Gender			
female	24 (86%)	1 (25%)	0.02
male	4 (14%)	3 (75%)	
Race			
white	26 (93%)	4 (100%)	1
black	2 (7%)	0 (0%)	
Ethnicity			
Hispanic	17 (61%)	1 (25%)	0.3
Comorbidities			
neurologic disease	8 (29%)	0 (0%)	0.55
diabetes	4 (14%)	0 (0%)	1
back surgery	4 (14%)	0 (0%)	1
prior BOO	1 (4%)	2 (50%)	0.03
Initial Visit PVR (mL)	65	675	<0.01
Catheter dependency	7 (25%)	4 (100%)	<0.01
Urodynamics Parameters			
PVR on UDS (mL)	220	535	<0.01

#### **Results and interpretation**



# Conclusions

- Our study provides insights into the factors influencing treatment outcomes following SNM in patients with UAB.
- SNS can be an effective treatment option for patients with UAB – the high proportion of patients who progressed to second stage SNS indicates that the therapy is welltolerated and efficacious.
- Despite the multifactorial nature of treatment response, our study identifies male gender and average post-void residual (PVR) volume as potential factors associated with SNM success in this population.
- Our findings contribute to bridging the knowledge gap regarding the application and determinants of SNM success specifically in UAB
- We highlight the need for comprehensive patient evaluation and assessment, including detailed medical history and urodynamic evaluation, to optimize treatment strategies and improve outcomes for patients with this challenging condition
- Data may serve as guidance for clinicians in selecting

Pdet max (cM H2O)	18.7	14.8	0.52
Pdet at Qmax (cm H2O)	13	n/a	
Qmax (mL/s)	8.7	n/a	
Qavg (mL/s)	3.2	n/a	
End filling Pdet (cm H2O)	9.5	n/a	
Valsalva voiding	15 (54%)	n/a	
Unable to void	13 (46%)	4 (100%)	0.1

#### **Table 1. Urodynamic Variables**

- The urodynamic profile of patients who progressed to second stage SNS was characterized by lower PVR compared to those who did not progress.
- Patients who require CIC may be less responsive to SNS therapy.
- Patients with prior BOO procedures may have lower success

appropriate candidates for SNS therapy and managing patient expectations.

### References

1. Janssen, D. A., Martens, F. M., de Wall, L. L., van Breda, H. M. & Heesakkers, J. P. Clinical utility of neurostimulation devices in the treatment of overactive bladder: current perspectives. Med Devices (Auckl) 10, 109–122 (2017).

2. Bayrak, Ö. & Dmochowski, R. R. Underactive bladder: A review of the current treatment concepts. Turk J Urol 45, 401–409 (2019).

3. Nobrega, R. P., Solomon, E., Jenks, J., Greenwell, T. & Ockrim,
J. Predicting a successful outcome in sacral neuromodulation testing: Are urodynamic parameters prognostic? Neurourology and Urodynamics 37, 1007–1010 (2018)